Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
Disc Medicine (NASDAQ:IRON) announced upcoming clinical data presentation at the 2024 American Society of Nephrology (ASN) Kidney Week, October 24-27, 2024, in San Diego. The presentation will feature additional data from Phase 1b trial of DISC-0974 in patients with non-dialysis dependent chronic kidney disease (NDD CKD) and anemia.
The poster will report on 40mg and 60mg dose cohorts, focusing on safety, pharmacokinetics, and effects of DISC-0974 on hepcidin, iron, and anemia. The randomized, placebo-controlled study aims to assess safety and changes to hepcidin, iron, and key hematologic parameters.
Dr. Pablo Pergola will present the abstract titled "A Phase 1b, Double-Blind, Placebo-Controlled Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Non-Dialysis-Dependent Chronic Kidney Disease and Anemia" on Friday, October 25, 2024.
Disc Medicine (NASDAQ:IRON) ha annunciato la presentazione di dati clinici in arrivo durante la Kidney Week 2024 dell'American Society of Nephrology (ASN), dal 24 al 27 ottobre 2024, a San Diego. La presentazione includerà dati aggiuntivi dalla sperimentazione di Fase 1b di DISC-0974 in pazienti con malattia renale cronica non-dialisi dipendente (NDD CKD) e anemia.
Il poster riporterà sui coorti dosi di 40mg e 60mg, concentrandosi su sicurezza, farmacocinetica e sugli effetti di DISC-0974 su hepcidina, ferro e anemia. Lo studio randomizzato, controllato con placebo, ha l'obiettivo di valutare la sicurezza e i cambiamenti a hepcidina, ferro e parametri ematologici chiave.
Il Dr. Pablo Pergola presenterà l'abstract intitolato "Uno studio di fase 1b, in doppio cieco, controllato con placebo su DISC-0974, un anticorpo anti-emojuvelina, in pazienti con malattia renale cronica non-dialisi dipendente e anemia" venerdì 25 ottobre 2024.
Disc Medicine (NASDAQ:IRON) anunció una próxima presentación de datos clínicos en la Semana del Riñón 2024 de la Sociedad Americana de Nefrología (ASN), del 24 al 27 de octubre de 2024, en San Diego. La presentación contará con datos adicionales del ensayo de Fase 1b de DISC-0974 en pacientes con enfermedad renal crónica no dependiente de diálisis (NDD CKD) y anemia.
El póster informará sobre cohorte de dosis de 40mg y 60mg, centrándose en la seguridad, farmacocinética y efectos de DISC-0974 sobre hepcidina, hierro y anemia. El estudio aleatorizado, controlado con placebo, tiene como objetivo evaluar la seguridad y los cambios en hepcidina, hierro y parámetros hematológicos clave.
El Dr. Pablo Pergola presentará el resumen titulado "Un estudio de fase 1b, doble ciego, controlado con placebo de DISC-0974, un anticuerpo anti-hemojuvelina, en pacientes con enfermedad renal crónica no dependiente de diálisis y anemia" el viernes 25 de octubre de 2024.
Disc Medicine (NASDAQ:IRON)는 2024년 미국 신장학회(ASN) 신장 주간의 임상 데이터 발표를 2024년 10월 24일부터 27일까지 샌디에이고에서 발표할 예정이라고 전했습니다. 이번 발표에서는 비투석 의존 만성 신장 질환(NDD CKD) 및 빈혈 환자를 대상으로 한 1b상 시험의 추가 데이터가 포함됩니다.
포스터는 40mg 및 60mg 용량 코호트에 관한 내용을 보고하며, DISC-0974의 안전성, 약동학, 그리고 헵시딘, 철분 및 빈혈에 미치는 영향을 중점적으로 다룰 것입니다. 무작위 이중 맹검, 위약 대조 연구는 안전성과 헵시딘, 철분 및 주요 혈구학적 매개변수의 변화를 평가하는 것을 목표로 하고 있습니다.
파블로 페르골라 박사는 2024년 10월 25일 금요일에 "비투석 의존 만성 신장 질환 및 빈혈 환자를 위한 DISC-0974의 1b상, 이중 맹검, 위약 대조 연구"라는 제목의 초록을 발표할 것입니다.
Disc Medicine (NASDAQ:IRON) a annoncé une prochaine présentation de données cliniques lors de la Kidney Week 2024 de l'American Society of Nephrology (ASN), qui se tiendra du 24 au 27 octobre 2024 à San Diego. La présentation inclura des données supplémentaires de l'essai de phase 1b de DISC-0974 chez des patients atteints de maladie rénale chronique non-dialyse-dépendante (NDD CKD) et d'anémie.
Le poster fera rapport sur les cohortes de doses de 40mg et 60mg, en mettant l'accent sur la sécurité, la pharmacocinétique et les effets de DISC-0974 sur l'hepcidine, le fer et l'anémie. L'étude randomisée, contrôlée par placebo, vise à évaluer la sécurité et les modifications de l'hepcidine, du fer et des principaux paramètres hématologiques.
Le Dr Pablo Pergola présentera l'abstract intitulé "Une étude de phase 1b, en double aveugle, contrôlée par placebo de DISC-0974, un anticorps anti-Hemojuvelin, chez des patients atteints de maladie rénale chronique non dialyse-dépendante et d'anémie" le vendredi 25 octobre 2024.
Disc Medicine (NASDAQ:IRON) kündigte die bevorstehende Präsentation klinischer Daten während der Kidney Week 2024 der American Society of Nephrology (ASN) an, die vom 24. bis 27. Oktober 2024 in San Diego stattfindet. Die Präsentation wird zusätzliche Daten aus der Phase 1b-Studie von DISC-0974 bei Patienten mit nicht dialyseabhängiger chronischer Nierenerkrankung (NDD CKD) und Anämie enthalten.
Das Poster wird über 40 mg- und 60 mg-Dosisgruppen berichten, wobei der Schwerpunkt auf Sicherheit, Pharmakokinetik und den Auswirkungen von DISC-0974 auf Hepcidin, Eisen und Anämie liegen wird. Die randomisierte, placebo-kontrollierte Studie zielt darauf ab, die Sicherheit und Veränderungen von Hepcidin, Eisen und wichtigen hämatologischen Parametern zu bewerten.
Dr. Pablo Pergola wird am Freitag, den 25. Oktober 2024, das Abstract mit dem Titel "Eine Phase 1b, doppelblinde, placebo-kontrollierte Studie von DISC-0974, einem Anti-Hemojuvelin-Antikörper, bei Patienten mit nicht dialyseabhängiger chronischer Nierenerkrankung und Anämie" präsentieren.
- Presentation of new clinical data from Phase 1b trial of DISC-0974
- Expansion of dose cohorts to include 40mg and 60mg doses
- Study focuses on safety and efficacy in NDD CKD patients with anemia
- None.
Insights
This presentation of new data from the Phase 1b trial of DISC-0974 in CKD patients with anemia is moderately impactful for Disc Medicine. Key points to consider:
- The study focuses on safety and efficacy markers (hepcidin, iron and hematologic parameters) for DISC-0974 in non-dialysis dependent CKD patients.
- New data from higher dose cohorts (40mg and 60mg) will be presented, potentially showing dose-dependent effects.
- Positive safety and efficacy signals could support advancing DISC-0974 to later-stage trials for this indication.
- However, this is still early-stage data (Phase 1b) and more extensive studies will be needed to fully assess the drug's potential.
For investors, this update provides insight into the drug's development progress but doesn't yet offer definitive proof of clinical success or market potential. The presentation at a major nephrology conference does increase visibility for Disc Medicine's pipeline.
WATERTOWN, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced upcoming clinical data to be presented at the 2024 American Society of Nephrology (ASN) Kidney Week, which will be held in San Diego, CA on October 24-27, 2024. The poster will report on additional SAD cohorts from the Phase 1b, randomized, placebo-controlled study of DISC-0974 in patients with non-dialysis dependent chronic kidney disease (NDD CKD) and anemia. This study was designed to assess safety as well as changes to hepcidin, iron, and key hematologic parameters.
“We are excited to present an update from our ongoing Phase 1b SAD study of DISC-0974 in NDD-CKD patients with anemia at the upcoming Kidney Week,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc. “At the meeting, we’ll be sharing data from the 40mg and 60mg dose cohorts on safety, pharmacokinetics, and effects of DISC-0974 on hepcidin, iron and anemia.”
The abstract is now available through the ASN Kidney Week conference website.
Details of Presentation
Abstract Number: 4126178
Title: A Phase 1b, Double-Blind, Placebo-Controlled Study of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients with Non-Dialysis-Dependent Chronic Kidney Disease and Anemia
Date / Time: Friday, October 25, 10:00am – 12:00pm PST
Presenter: Pablo Pergola, M.D., Ph.D.
About Disc Medicine
Disc Medicine is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.
Disc Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, express or implied statements regarding Disc’s expectations with respect to its phase 1b clinical study of DISC-0974 in NDD-CKD patients with anemia, the results thereof, and anticipated timing of release of data; and projected timeline for the initiation of the MAD portion of this clinical study. The use of words such as, but not limited to, “believe,” “expect,” “estimate,” “project,” “intend,” “future,” “potential,” “continue,” “may,” “might,” “plan,” “will,” “should,” “seek,” “anticipate,” or “could” or the negative of these terms and other similar words or expressions that are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Disc’s current beliefs, expectations and assumptions regarding the future of Disc’s business, future plans and strategies, clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Disc may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and investors should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of a number of material risks and uncertainties including but not limited to: the adequacy of Disc’s capital to support its future operations and its ability to successfully initiate and complete clinical trials; the nature, strategy and focus of Disc; the difficulty in predicting the time and cost of development of Disc’s product candidates; Disc’s plans to research, develop and commercialize its current and future product candidates; the timing of initiation of Disc’s planned preclinical studies and clinical trials; the timing of the availability of data from Disc’s clinical trials; Disc’s ability to identify additional product candidates with significant commercial potential and to expand its pipeline in hematological diseases; the timing and anticipated results of Disc’s preclinical studies and clinical trials and the risk that the results of Disc’s preclinical studies and clinical trials may not be predictive of future results in connection with future studies or clinical trials and may not support further development and marketing approval; and the other risks and uncertainties described in Disc’s filings with the Securities and Exchange Commission, including in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2023, and in subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement speaks only as of the date on which it was made. None of Disc, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law.
Media Contact
Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com
Investor Relations Contact
Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com
FAQ
What is the purpose of Disc Medicine's Phase 1b trial for DISC-0974?
When and where will Disc Medicine (IRON) present the new DISC-0974 trial data?
What dose cohorts of DISC-0974 will be discussed in Disc Medicine's (IRON) presentation?
Who will present Disc Medicine's (IRON) DISC-0974 trial results at ASN Kidney Week 2024?
